Close Menu
July 14, 2020
Sponsored by
Agilent

Development of a Metagenomics-based Pathogen-Detection Assay for SARS-CoV-2 Research

GenomeWebinar

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

The assay under development at the University of Pennsylvania is based on a microarray platform of 8 arrays by 60,000 probes and detects all known viruses and other pathogenic bacteria, fungi, and parasites, covering more than 6,000 accessions of microorganisms associated with diseases.

The array-based technology can accurately detect an agent of interest, including SARS-CoV-2, in less than 24 hours. The assay includes probes covering all known pathogenic respiratory pathogens, including other coronaviruses from bats and other mammals, providing accurate and efficient detection of SARS-CoV-2 as well as the potential for detection of other respiratory pathogens as co-infecting agents that may contribute to severity of disease. 

Dr. Erle Robertson of the University of Pennsylvania will describe the benefits of the test, which include high accuracy due to the use of multiple probes across the genome, which minimizes negative results from probe failure due to the compensatory signals from other probes in the assay screen. 

Dr. Robertson will discuss his team’s plans to develop the assay to require only a few drops of blood or plasma for detection of the virus.    

Disclaimer: Agilent products are NOT approved for COVID-19 testing, diagnosis, treatment, or mitigation. Agilent has not validated a product to detect the novel coronavirus.

For Research Use Only. Not for use in diagnostic procedures.

Sponsored by

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.